ASX:CSL

CSL Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume869,289 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield0.95%
BetaN/A

Receive CSL News and Ratings via Email

Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter.


CSL logo

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.49 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.8Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











CSL (ASX:CSL) Frequently Asked Questions

What stocks does MarketBeat like better than CSL?

Wall Street analysts have given CSL a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CSL wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were CSL's earnings last quarter?

CSL Limited (ASX:CSL) announced its quarterly earnings results on Wednesday, August, 14th. The company reported $4.24 earnings per share for the quarter, beating analysts' consensus estimates of $4.22 by $0.01.
View CSL's earnings history
.

How often does CSL pay dividends? What is the dividend yield for CSL?

CSL declared a Final dividend on Thursday, August 19th. Investors of record on Wednesday, September 29th will be given a dividend of 1.614 per share on Wednesday, September 29th. This represents a yield of 0.53%. The ex-dividend date of this dividend is Wednesday, September 1st. This is a positive change from CSL's previous Final dividend of A$1.48.
View CSL's dividend history
.

Is CSL a good dividend stock?

CSL pays an annual dividend of A$2.94 per share and currently has a dividend yield of 0.95%. The dividend payout ratio of CSL is 41.29%. This payout ratio is at a healthy, sustainable level, below 75%.
View CSL's dividend history.

Who are CSL's key executives?

CSL's management team includes the following people:
  • Mr. Paul R. Perreault B.A., MD, CEO & Exec. Director (Age 64, Pay $4.23M)
  • Dr. Paul F. McKenzie, Chief Operating Officer (Age 55, Pay $2.74M)
  • Dr. Robert Andrew Cuthbertson A.O., BMedSci, MBBS, Ph.D., FTSE, FAHMS, AO, Sr. Adviser & Exec. Director (Age 66, Pay $1.48M)
  • Ms. Joy Carolyn Linton B.Com., BComm, Grad Dip AFI, GAICD, Chief Financial Officer (Age 56)
  • Mr. Mark Dehring, Head of Investor Relations
  • Mr. Gregory Boss B.S., BS(Hons), J.D., Exec. VP of Legal & Group Gen. Counsel (Age 60)
  • Christina Hickie, Sr. Mang. of Communications
  • Ms. Elizabeth Walker B.A., M.S., Exec. VP & Chief HR Officer (Age 51)
  • Dr. Karen Etchberger, Exec. VP of Quality & Bus. Services (Age 63)
  • Ms. Sharon McHale, Head of Public Affairs

Who are some of CSL's key competitors?

What other stocks do shareholders of CSL own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CSL investors own include BHP Group (BHP), Commonwealth Bank of Australia (CBA), Cochlear (COH), ResMed (RMD), Telstra (TLS), Woodside Petroleum (WPL), Altium (ALU), Afterpay (APT), Appen (APX) and Berkshire Hathaway (BRK.B).

What is CSL's stock symbol?

CSL trades on the ASX under the ticker symbol "CSL."

How much money does CSL make?

CSL has a market capitalization of $0.00 and generates $10.31 billion in revenue each year.

How many employees does CSL have?

CSL employs 12,000 workers across the globe.

What is CSL's official website?

The official website for CSL is www.csl.com.au.

Where are CSL's headquarters?

How can I contact CSL?

CSL's mailing address is 45 Poplar Road,, Parkville, MELBOURNE, VIC 3052, Australia. The company can be reached via phone at +61-3-93891911.


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.